

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 600 744 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
04.03.1998 Bulletin 1998/10

(51) Int. Cl.⁶: C07K 5/103, A61K 38/07

(21) Application number: 93309707.3

(22) Date of filing: 03.12.1993

(54) Tumor inhibiting tetrapeptides bearing modified phenethyl amides

Tumorphinhibierende Tetrapeptide mit modifizierten Phenethylamid-Gruppen

Tetrapeptides portants des phenethylamides modifiés comme inhibiteurs de tumeurs

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 03.12.1992 US 985827

(43) Date of publication of application:
08.06.1994 Bulletin 1994/23

(73) Proprietor:
ARIZONA BOARD OF REGENTS
Tempe Arizona 85287 (US)

(72) Inventors:
• Pettit, George R.
Paradise Valley, AZ 85253 (US)
• Barkoczy, Jozsef
Budapest (HU)

(74) Representative:
Coxon, Philip et al
Eric Potter & Clarkson
St. Mary's Court
St. Mary's Gate
Nottingham NG1 1LE (GB)

(56) References cited:
US-A- 4 978 744

- CHEMICAL ABSTRACTS, vol. 118, no. 25, June 21, 1993 Columbus, Ohio, USA BECKWITH, MARGARET et al. "Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15." page 42, column 1, abstract-no. 247 085p; & J.Natl.Cancer Inst.1993, 85(6), 483-8 (Eng.).
- CHEMICAL ABSTRACTS, vol. 115, no. 17, October 28, 1991 Columbus, Ohio, USA SHIOIRI, TAKAYUKI et al. "A synthetic study on dolastatin 10, an antineoplastic peptide of marine origin." page 989, column 2, abstract-no. 183 880x; & Pept.1990, Proc.Eur.Pept. Symp., 21st 1990 (Pub.1991), 104-6 (Eng.).
- CHEMICAL ABSTRACTS, vol. 114, no. 21, May 27, 1991 Columbus, Ohio, USA HAMADA, YASUMASA et al. "New methods and reagents for organic synthesis. 95. Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from sea hare." page 884, column 1, abstract-no.207 802f; & Tetrahedron Lett. 1991, 32(7), 931-4 (Eng.).
- CHEMICAL ABSTRACTS, vol. 119, no. 5, August 2, 1993 Columbus, Ohio, USA SHIOIRI, TAKAYUKI et al. "Stereoselective synthesis of dolastatin 10 and its congeners." page 1005, column 1, abstract-no. 49 880b; & Tetrahedron 1993, 49(9), 1913-24 (Eng.).

EP 0 600 744 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

This invention relates generally to the field of antineoplastic compounds, and more particularly to the design and synthesis of selected tetra-peptides bearing modified phenethylamides, exhibiting tumor inhibitory effects.

Ancient marine invertebrate species of the Phyla Bryozoa, Mollusca, and Porifera have been well established in the oceans for over one billion years. Such organisms have undergone trillions of biosynthetic reactions of their evolutionary chemistry to reach their present level of cellular organization, regulation and defense.

For example, marine sponges have changed minimally in physical appearance for nearly 500 million years. This suggests a very effective chemical resistance to evolution in response to changing environmental conditions over that period of time. Recognition of the potential for utilizing this biologically potent marine animal for medicinal purposes was recorded in Egypt about 2,700 BC and by 200 BC sea hare extracts were being used in Greece for their curative affect. This consideration along with the observation that marine animals, e.g. invertebrates and sharks, rarely develop cancer led to the systematic investigation of marine animal and plant anticancer compounds.

By 1968 ample evidence had been obtained, based on the U.S. National Cancer Institute's (NCI) key experimental cancer study systems, that certain marine organisms could provide new and antineoplastic and/or cytotoxic agents and might also lead to compounds which would be effective in the control and/or eradication of viral diseases.

Further, these marine organisms were believed to possess potentially useful drug candidates of unprecedented structure which had eluded discovery by other methods of medicinal chemistry. Fortunately, these expectations have been realized, e.g. the discovery of the bryostatins, dolastatins and cephalostatins, many of which are now in preclinical development or human clinical studies.

Those researchers presently involved in medicinal chemistry know well the time lag between the isolation of a new compound and its introduction to the market. Often this procedure takes several years and may take decades. As a result, industry, in association with the U.S. Government, has developed a system of testing criteria which serves two purposes. One is to eliminate those substances which are shown through testing to be economically counterproductive. The second, more important purpose serves to identify those compounds which demonstrate a high likelihood of success and therefore warrant the further study and qualification, and attendant expense, necessary to meet the stringent regulatory requirements which control the ultimate market place.

The current cost to develop the necessary data approaches ten million dollars per compound. As such, economics dictate that such a huge investment will be made only when there is a reasonable opportunity for it to be recovered. Absent such opportunity, there will be no investment and the research involving the discovery of these potentially life saving compounds will cease. Only two hundred years ago many diseases ravaged mankind. Many of these now have been controlled or eradicated. During the advancement of means to treat or eliminate these diseases, work with appropriate animals was of critical importance.

Current research in the control of cancer in the United States is coordinated by the National Cancer Institute (NCI). To determine whether a substance has anti-cancer properties, the NCI has established a systematic protocol. This protocol, which involves the testing of a substance against a standard cell line panel containing 60 human tumor cell lines, has been verified and has been accepted in scientific circles. The protocol, and the established statistical means for analyzing the results obtained by the standardized testing are fully described in the literature. See: Boyd, Dr. Michael R., Principles & Practice of Oncology, PPO Updates, Volume 3, Number 10, October 1989, for an in depth description of the testing protocol; and Paull, K. D., "Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines; Development of Mean Graph and COMPARE Algorithm", Journal of the National Cancer Institute Reports, Vol. 81, No. 14, Page 1088, July 14, 1989 for a description of the methods of statistical analysis. Both of these references are incorporated herein by this reference thereto.

Numerous substances have been discovered which demonstrate significant antineoplastic or tumor inhibiting characteristics. As stated above, many of these compounds have been extracted, albeit with great difficulty, from marine animals such as the sponge and sea hare. Once isolation and testing of these compounds has been accomplished, a practical question remains, namely how to produce commercially significant quantities of the desired substance.

Quinine, which is available in practical quantities from the bark of the cinchona plant, differs from the compounds which are extracts of marine creatures possessing antineoplastic qualities. The collection and processing of these later compounds from their natural sources ranges from grossly impractical to the utterly impossible. Ignoring the ecological impact, the population of these creatures and the cost of collection and extraction make the process unworkable. Artificial synthesis of the active compounds is the only possible solution.

Therefore, the elucidation of the structure of these antineoplastic compounds is essential. After the structure has been determined, then a means of synthesis must be determined. This is often a long and arduous procedure due to the idiosyncratic complexity of these naturally occurring, evolutionary modified compounds. In addition, research is necessary to determine whether any portion of the naturally occurring compound is irrelevant to the desired properties, so that focus can be on the simplest structure having the perceived properties.

Various species of sponges and sea hares produce cyclic and linear peptides that contain amino acids which have

been shown to be effective in the treatment and/or control of cancer in humans. For example, Dolastatin 10 (U.S. Pat. No. 4,816,444), which has only recently been synthesized, has proven to be a potent antineoplastic substance. This finding, in turn, has prompted research into other compounds related to Dolastatin 10.

Accordingly a principle object of this invention is to provide a new agent useful in the retardation or remission of one or more types of cancer.


A further object of the present invention is to provide methods and procedures for designing and synthesizing selected tetrapeptides bearing modified phenethylamides for the treatment of neoplastic diseases and the inhibition of tumor growth.

These and still further objects, as shall hereinafter appear, are readily fulfilled by the present invention in a remarkably unexpected manner as will be readily discerned from the following detailed description of an exemplary embodiment thereof.

The discovery of new types of potentially antineoplastic peptides presents one of the most essential and promising approaches to a synthesis of new anticancer and immunosuppressant drugs. The dolastatins, an unprecedented series of linear and cyclic antineoplastic and/or cytostatic peptides isolated from Indian Ocean sea hare Dolabella auricularia (See: Pettit et al., J. Am. Chem. Soc., 1976, 98, 4677) have shown excellent antineoplastic activity. The very productive sea hare D. auricularia has produced many structurally distinct peptides. Presently Dolastatin 10, a linear tetrapeptide, represents the most important member as a potentially useful antineoplastic activity profiles against various cancer screens presently known (See: Pettit et al., J. Am. Chem. Soc., 1987, 109, 6883). Recently reported is the total synthesis and absolute configuration of this structurally unique and biologically active peptide (See: Pettit et al., J. Am. Chem. Soc., 1989, 111, 5463). Subsequent to this report, this compound attracted considerable interest in the research community (See e.g., Hamada et al., Tetrahedron Lett., 1991, 32, 931, Hayashi et al., Peptide Chemistry, 1989, 291 and Tomioka et al., Tetrahedron Lett., 1991, 32(21), 2395-2398).


A series of Dolastatin 10 chiral isomers has been documented (See: Pettit et al., J. Med. Chem., 1990, 33, 3132). More recently these experiments were extended to synthesis of R-Doe-isodolastatin 10. We have now found that the R-dolaphenine (Doe) substitution does not result in any significant difference in its human cancer cell line activity when compared with Dolastatin 10. This fact suggested that the 2-thiazolyl unit could be replaced with a simple amide. The amide molecular length was then examined, starting with benzylamine, phenethylamine and 3-phenyl-1-propylamine. Also studied was a systematic series of modifications at the dolaphenine position introducing a substituted nitrogen instead of a phenyl ring.

Then, fixing the length of the side chain at n=2 shows the importance of substituting the phenyl ring and the aliphatic side chain in the amide part. Next investigated was the role of placing substituents on the phenyl ring using electron withdrawing (4-nitro, 4-chloro, 4-fluoro, 4-bromo, 3-chloro, 2-chloro) and electron releasing (3,4-dimethoxy) groups. The corresponding amine (2a-g) was allowed to react with dolaproine (1). Synthesis of amides 3a-g using diethyl phosphorocyanidate (DEPC) for condensation led to an excellent yield. No racemization was observed during this reaction. Synthesis followed and the (3a-g) amides are shown below:




The protecting groups of amides 2a-g were removed with trifluoroacetic acid to afford the trifluoroacetate salt 4a-g as shown below:

Trifluoroacetate salt 4a-g






Diethyl phosphorocyanidate (DEPC) was used again with excellent results for coupling the tripeptide 5 with each of the trifluoroacetate salts 4a-g to yield dolastatin 10 structural modification 6a-g according to the following reaction:

Synthesis of Peptides 6a-g



Next investigated was the effect of substituting the aliphatic chain and the amide nitrogen in the modified dolaphe-
 nine position using unsubstituted phenyl ring. Then methyl and hydroxyl substituents were applied starting with (1R,
 2R)-2-methylamino-1-phenylpropanol (2h), (1S, 2R)-norephedrine (2i), D(+)-(1S, 2S)-norephedrine (2j), and (1R, 2S)-
 norephedrine (2k). Synthesis of modified tetrapeptide phenethylamides 6h-k was achieved by the methods developed
 for amides 6a-g according to the reactions shown below:





In a preferred embodiment of the present invention, the synthesis of the constituent intermediate structures is performed by the following steps.

Synthesis of Amides 3a-k (shown above). General Procedure A

To a solution of [2S-[2R*(α S*, β S*)]-1-[(1, 1-dimethyl-ethoxy) carbonyl]- β -methoxy- α -methyl-2-pyrrolidine-propa-
 5 noic acid (t-Boc-Dolaproine, 1, 0.144 g, 0.5 mmol) in dichloromethane (3 ml, distilled from CaH₂) was added the respec-
 tive amine (2a-k 0.5 mmol) followed by triethylamine (0.077 ml, 0.55 mmol) and diethyl phosphoro-cyanidate (DEPC,
 0.09 ml, 93%, 0.55 mmol, ice bath) and the solution was stirred under argon for two hours. The solvent was removed
 (under vacuum at room temperature) and the residue was chromatographed (silica gel column using hexane-acetone
 3:1 as eluent). After the evaporation of solvent from the fractions (selected by TLC) 2 ml dry dichloromethane was added
 and evaporation was repeated. The residue was dried in a desiccator under vacuum overnight to afford the amide (3a-
 10 k) as a viscous oil.

[2S-[2R*[1S*,2S*]]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(3,4-dimethoxy-phenyl)-ethyl]amino]propyl]-1-pyrrolidi-
 necarboxylic acid, 1,1-dimethylethylester (3a)

15 Compound 3a was synthesized from t-Boc-Dolaproine (1) and 3, 4-dimethoxyphenethylamine (2a) according to
 General Procedure A.

Yield 3a: 0.189 g (84%)
 [α]_D²⁵ = -33 ° (c=1.6 g/cm³, CHCl₃)
 20 Anal. Calcd for C₂₄H₃₈N₂O₆, M. w. 450.566

[2S-[2R*[1S*, 2S*]]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-nitro-phenyl)-ethyl]amino] propyl]-1-pyrrolidine-car-
 boxylic acid, 1,1-dimethylethylester (3b)

25 Compound 3b was synthesized from t-Boc-Dolaproine (1) and 4-nitrophenethylamine (2b) according to General
 Procedure A.

Yield 3b: 0.176 g (81%)
 [α]_D²⁵ = -54 ° (c=0.29 g/cm³ in CHCl₃)
 30 Anal. Calcd for C₂₂H₃₃N₃O₆ M. w.: 435.505

[2S-[2R*[1S*, 2S*]]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-chloro-phenyl)-ethyl] amino] propyl]-1-pyrrolidine-
 carboxylic acid, 1,1-dimethylethylester (3c)

35 Compound 3c was synthesized from t-Boc-Dolaproine (1) and 2-(4-chloro-phenyl)-ethylamine (2c) according to
 General Procedure A.

Yield 3c: 0.183 g (85.5%)
 [α]_D²⁵ = -38 ° (c=1.52 g/cm³ in CHCl₃)
 40 Anal. Calcd for C₂₂H₃₃N₂O₄Cl M. w.: 424.953

[2S-[2R*[1S*, 2S*]]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-fluoro-phenyl)-ethyl]amino] propyl]-1-pyrrolidinocar-
 boxylic acid, 1,1-dimethylethylester (3d)

45 Compound 3d was synthesized from t-Boc-Dolaproine (1) and 2-(4-fluoro-phenyl)-ethylamine (2d) according to
 General Procedure A.

Yield 3d: 0.192 g (94.3%)
 [α]_D²⁵ = -37.70 ° (c=1.61 g/cm³ in CHCl₃)
 50 M. w.: 408.5 C₂₂H₃₃N₂O₄F

[2S-[2R*[1S*, 2S*]]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-bromo-phenyl)-ethyl]amino]propyl]-1-pyrrolidinecar-
 boxylic acid, 1,1-dimethylethylester (3e)

55 Compound 3e was synthesized from t-Boc-Dolaproine (1) and 2-(4-bromo-phenyl)-ethylamine (2e) according to
 General Procedure A.

Yield 3e: 0.193 g (82.1%)

$[\alpha]_{\text{D}}^{25} = -29.67^\circ$ ($c = 1.52 \text{ g/cm}^3$ in CHCl_3)

M. w.: 469.49 $\text{C}_{22}\text{H}_{33}\text{N}_2\text{O}_4\text{Br}$

5 **[2S-[2R*][1S*, 2S*]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(3-chloro-phenyl)-ethyl]amino]propyl]-1-pyrrolidine-carboxylic acid, 1,1-dimethylethylester (3f)**

Compound 3f was synthesized from t-Boc-Dolaproine (1) and 2-(3-chloro-phenyl)-ethylamine (2f) according to General Procedure A.

10 Yield 3f: 0.202 g (95.3%)

$[\alpha]_{\text{D}}^{25} = -30.95^\circ$ ($c = 1.15 \text{ g/cm}^3$ in CHCl_3)

M. w.: 424.953 $\text{C}_{22}\text{H}_{33}\text{N}_2\text{O}_4\text{Cl}$

15 **[2S-[2R*][1S*, 2S*]]-2-[1-methoxy-2-methyl-3-oxo-3-[[2-(2-chloro-phenyl)-ethyl]amino]propyl]-1-pyrrolidine-carboxylic acid, 1,1-dimethylethylester (3g)**

Compound 3g was synthesized from t-Boc-Dolaproine (1) and 2-(2-chloro-phenyl)-ethylamine (2g) according to General Procedure A.

20 Yield 3g: 0.194 g (91.7%)

$[\alpha]_{\text{D}}^{25} = -39.36^\circ$ ($c = 1.71 \text{ g/cm}^3$ in CHCl_3)

M. w.: 424.953 $\text{C}_{22}\text{H}_{33}\text{N}_2\text{O}_4\text{Cl}$

25 **[2S-[2R*][1S*, 2S*, 3(1S*, 2S*)]]-2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]methyl-amino]propyl]-1-pyrrolidinecarboxylic acid, 1,1-dimethylethylester (3h)**

Compound 3h was synthesized from t-Boc-Dolaproine (1) and (1R, 2R)-(-)-2-methylamino-1-phenyl-propan-1-ol (2h) according to General Procedure A.

30 Yield 3h: 0.14 g (64%)

$[\alpha]_{\text{D}}^{25} = -184.7^\circ$ ($c = 0.17 \text{ g/cm}^3$ in CHCl_3)

Anal. Calcd for $\text{C}_{24}\text{H}_{38}\text{N}_2\text{O}_5$ M. w. 434.56

35 **[2S-[2R*][1S*, 2S*, 3(1R*, 2S*)]]-2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]amino]propyl]-1-pyrrolidinecarboxylic acid, 1,1-dimethylethylester (3i)**

Compound 3i was synthesized from t-Boc-Dolaproine (1) and (1S, 2R)-norephedrine (2i) according to General Procedure A. In this case at the end drying colorless crystals were obtained.

40 Yield 3i: 0.145 g (69%)

M. p.: 55-57 °C

$[\alpha]_{\text{D}}^{25} = +8.8^\circ$ ($c = 0.42 \text{ g/cm}^3$ in CHCl_3)

Anal. Calcd for $\text{C}_{23}\text{H}_{36}\text{N}_2\text{O}_5$ M. w. 420.54

45 **[2S-[2R*][1S*, 2S*, 3(1R*, 2R*)]]-2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]amino]propyl]-1-pyrrolidinecarboxylic acid, 1,1-dimethylethylester (3j)**

Compound 3j was synthesized from t-Boc-Dolaproine (1) and D-(+)-(1S, 2S)-norephedrine (2j) according to General Procedure A. In this case at the end drying colorless crystals were obtained.

50 Yield 3j: 0.204 g (97.6%)

M. p.: 65-67 °C

$[\alpha]_{\text{D}}^{25} = +7.0^\circ$ ($c = 0.43 \text{ g/cm}^3$ in CHCl_3)

M. w.: 420.54 $\text{C}_{23}\text{H}_{36}\text{N}_2\text{O}_5$

55

[2S-[2R*(1S*, 2S*, 3(1S*, 2R*))]]-2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl] amino]propyl]-1-pyrrolidinecarboxylic acid, 1,1-dimethylethylester (**3k**)

Compound **3k** was synthesized from t-Boc-Dolaproine (**1**) and (1R, 2S)-norephedrine (**2k**) according to General Procedure A. In this case at the end drying colorless crystals were obtained.

Yield **3k**: 0.201 g (96.0%)
 M. p.: 53-55 °C
 $[\alpha]_D^{25} = -38.9^\circ$ (c=0.36 g/cm³ in CHCl₃)
 M. w.: 420.54 C₂₃H₃₆N₂O₅

Synthesis of Peptides **6a-k** (shown above). General Procedure B.

A solution of the amide **3a-k** (0.2 mmol) in dichloromethane (2 ml) and trifluoroacetic acid (2 ml) was stirred (ice bath under an argon atmosphere) for two hours. The solvent was removed under reduced pressure and the residue dissolved in toluene. Solvent was again removed in vacuum and this operation was repeated. The residue was dried in a desiccator (under vacuum overnight) to afford the trifluoroacetate salt **4a-k** as a viscous oil.

To a solution of the trifluoroacetate salt **4a-k** (0.2 mmol) in dichloromethane (2 ml, distilled from CaH₂) was added the tripeptide (synthesis previously reported) trifluoroacetate salt (**5**, 0.109 g, 0.2 mmol) followed by triethylamine (0.088 ml, 0.63 mmol) and diethyl phosphorocyanidate (DEPC, 0.036 ml, 93%, 0.22 mmol, ice bath). The solution was stirred under argon for two hours. The solvent was removed (under vacuum at room temperature) and the residue was chromatographed (silica gel column using acetone/hexane 3:2 as eluent). After the evaporation of solvent from the fractions (selected by TLC behavior) 2 ml of dry dichloromethane was added evaporated. The residue was dried in a desiccator under vacuum overnight to yield a white fluffy solid.

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(3,4-dimethoxy-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxo butyl]-N-methyl-L-valineamide (**6a**)

Compound **6a** was synthesized from trifluoroacetate salt **4a** (from amide **3a**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6a**: 128 mg (84%)
 M. p.: 145-147 °C
 $[\alpha]_D^{25} = -32^\circ$ (c=0.2 g/cm³ in CHCl₃)
 Anal. Calc.: C₄₁H₇₁N₅O₈ Mw.: 762.018

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-nitro-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxobutyl]-N-methyl-L-valineamide (**6b**)

Compound **6b** was synthesized from trifluoroacetate salt **4e** (from amide **3b**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6b**: 129 mg (87%)
 M. p.: 73-76 °C
 $[\alpha]_D^{25} = -45^\circ$ (c=0.08 g/cm³ in CHCl₃)
 Anal. Calc.: C₃₉H₆₆N₆O₈ Mw.: 746.965

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-chlor-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxobutyl]-N-methyl-L-valineamide (**6c**)

Compound **6c** was synthesized from trifluoroacetate salt **4c** (from amide **3c**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6c**: 125 mg (85%)
 M. p.: 75-78 °C
 $[\alpha]_D^{25} = -47.9^\circ$ (c=0.19 g/cm³ in CDCl₃)
 Anal. Calc.: C₃₉H₆₆N₅O₆Cl Mw.: 736.411

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-chlor-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxo butyl]-N-methyl-L-valineamide (**6d**)

Compound **6d** was synthesized from trifluoroacetate salt **4d** (from amide **3d**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6d** : 0.105 g (72.8%)

M. p.: 76-78 °C

$[\alpha]_{D25} = -44.81^\circ$ (c=0.27 g/cm³ in CHCl₃)

Anal. Calc. : C₃₉H₆₆N₅O₆F Mw.: 719.958

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(4-bromo-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxo butyl]-N-methyl-L-valineamide (**6e**)

Compound **6e** was synthesized from trifluoroacetate salt **4e** (from amide **3e**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6e** : 0.113 g (72.7%)

M. p.: 107-109 °C

$[\alpha]_{D25} = -41.76^\circ$ (c=0.17 g/cm³ in CDCl₃)

Anal. Calc. : C₃₉H₆₆N₅O₆Br Mw.: 780.867

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(3-chlor-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxo butyl]-N-methyl-L-valineamide (**6f**)

Compound **6f** was synthesized from trifluoroacetate salt **4f** (from amide **3f**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6f** : 0.103 g (69.7%)

M. p.: 79-81 °C

$[\alpha]_{D25} = -41.79^\circ$ (c=0.28 g/cm³ in CDCl₃)

Anal. Calc. : C₃₉H₆₆N₅O₆Cl Mw.: 736.411

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-(2-chlor-phenyl)-ethyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxo butyl]-N-methyl-L-valineamide (**6g**)

Compound **6g** was synthesized from trifluoroacetate salt **4g** (from amide **3g**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6g** : 0.105 g (71.3%)

M. p.: 75-77 °C

$[\alpha]_{D25} = -44.17^\circ$ (c=0.36 g/cm³ in CDCl₃)

Anal. Calc. : C₃₉H₆₆N₅O₆Cl Mw.: 736.411

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(1S*, 2S*)]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]methylamino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxobutyl]-N-methyl-L-valineamide (**6h**)

Compound **6h** was synthesized from trifluoroacetate salt **4g** (from amide **3h**) and tripeptide trifluoroacetate salt **5** by General Procedure B.

Yield **6h** : 92 mg (62%)

M. p.: 108-110 °C

$[\alpha]_{D25} = -70^\circ$ (c=0.13 g/cm³ in CHCl₃)

Anal. Calc. : C₄₁H₇₁N₅O₇ Mw.: 746.018

[2S-[1[1R*(R*),2S*],2R*[1S*,2S*, 3(1R*, 2S*)]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxobutyl]-N-methyl-L-valineamide (6i)

5 Compound 6i was synthesized from trifluoroacetate salt 4j (from amide 3i) and tripeptide trifluoroacetate salt 5 by General Procedure B.

Yield 6i: 0.101 g (69%)

M. p.: 92-94 °C

10 $[\alpha]_{25}^D$: -20 ° (c=0.12 g/cm³ in CDCl₃)

Anal. Calc. : C₄₀H₆₉N₅O₇ Mw.: 731. 992

15 [2S-[1[1R*(R*),2S*],2R*[1S*,2S*, 3(1R*,2R*)]]]-N, N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxobutyl]-N-methyl-L-valineamide (6j)

Compound 6j was synthesized from trifluoroacetate salt 4j (from amide 3j) and tripeptide trifluoroacetate salt 5 by General Procedure B.

20 Yield 6j: 0.110 g (75.4%)

M. p.: 108-110 °C

$[\alpha]_{25}^D$: -24.05 ° (c=0.37 g/cm³ in CHCl₃)

Anal. Calc. : C₄₀H₆₉N₅O₇ Mw.: 731.992

25 [2S-[1[1R*(R*),2S*],2R*[1S*,2S*, 3(1S*, 2R*)]]]-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[1-phenyl-1-hydroxy-2-propyl]amino]propyl]-1-pyrrolidinyl-1-(methylpropyl)-4-oxobutyl]-N-methyl-L-valine amide (6k)

30 Compound 6k was synthesized from trifluoroacetate salt 4k (from amide 3k) and tripeptide trifluoroacetate salt 5 by General Procedure B.

Yield 6k: 0.098 g (67%)

M. p.: 100-102 °C

$[\alpha]_{25}^D$: -39.26 ° (c=0.27 g/cm³ in CDCl₃)

35 Anal. Calc. : C₄₀H₆₉N₅O₇ Mw.: 731.992

The extraordinary inhibition of cell growth shown by the tetrapeptide 6a-k against six major types of human cancer and against the murine P388 lymphocytic leukemia cell line has been presented in Table 1-2, below.

40

45

50

55

Table 1. Biological activity of Peptides 6a-g

	Cell type	Cell line	<u>6a</u>	<u>6b</u>	<u>6c</u>	<u>6d</u>	<u>6e</u>	<u>6f</u>	<u>6g</u>
5	Mouse leukemia cell								
	ED-50 ($\mu\text{g/ml}$)	P-388	0.003500	0.045900	0.005530	0.00372	0.00515	0.00225	0.000289
10	Ovarian	OVCAR-3	0.000007	0.00024	<0.000001	0.000016	0.00015	<0.000001	<0.000001
	CNS	SF-295	0.000029	0.00035	0.000010	0.000046	0.00043	0.000028	<0.000001
15	Human cancer cell	Renal	A498	0.000016	0.00064	0.00062	0.000059	0.00046	<0.000001
	GI-50 ($\mu\text{g/ml}$)	Lung-NSC	NCI-460	0.000031	0.00028	<0.000001	0.000025	0.00027	<0.000001
	Cobn	KM20L2	0.000025	0.00030	<0.000001	0.00033	0.00032	0.0000007	<0.000001
20	Melanoma	SK-MEL-3	0.000018	0.00012	<0.000001	0.000044	0.00038	<0.000001	<0.000001
	Ovarian	OVCAR-3	0.000061	0.00065	<0.000001	0.000050	0.00050	<0.000001	<0.000001
25	CNS	SF-295	0.000083	>0.01	0.0019	>0.01	>0.01	>0.01	>0.01
	Human cancer cell	Renal	A498	>0.0001	>0.01	0.0028	>0.01	0.0017	0.002
30	TGI ($\mu\text{g/ml}$)	Lung-NSC	NCI-460	0.000094	0.0012	0.0011	0.00014	0.0012	0.00010
	Cobn	KM20L2	0.000061	0.0013	0.0011	0.0029	0.0041	0.0017	0.00038
	Melanoma	SK-MEL-3	0.000058	0.0013	>0.01	>0.01	>0.01	>0.01	>0.01
35	Ovarian	OVCAR-3	>0.0001	>0.01	>0.01	0.00096	0.0094	0.00076	>0.01
	CNS	SF-295	>0.0001	>0.01	>0.01	>0.0001	>0.01	>0.01	>0.01
40	Human cancer cells	Renal	A498	>0.0001	>0.01	>0.01	>0.0001	>0.01	>0.01
	LC-50 ($\mu\text{g/ml}$)	Lung-NSC	NCI-460	>0.0001	>0.01	>0.01	>0.0001	>0.01	>0.01
45	Cobn	KM20L2	>0.0001	>0.01	>0.01	>0.0001	>0.01	>0.01	>0.01
	Melanoma	SK-MEL-3	>0.0001	>0.01	>0.01	>0.0001	>0.01	>0.01	>0.01

50

55


Table 2

Biological activity of Peptides 6h-k						
	Cell type	Cell line	6h	6i	6j	6k
Mouse leukemia cells ED-50 ($\mu\text{g/ml}$)		P-388	0.001710	0.000503	0.000321	0.000434
Human cancer cells GI-50 ($\mu\text{g/ml}$)	Ovarian	OVCAR-3	0.00006	0.000021	0.0000097	0.00017
	CNS	SF-295	0.00031	0.000016	0.00034	0.00060
	Renal	A498	0.00099	0.0000027	0.000096	0.00075
	Lung-NSC	NCI-460	0.00006	0.000025	0.000026	0.00030
	Colon	KM20L2	0.00023	0.00011	0.000022	0.00029
	Melanoma	SK-MEL-3	0.00030	0.00058	0.000044	0.00058
Human cancer cells TGI ($\mu\text{g/ml}$)	Ovarian	OVCAR-3	0.0009	0.000042	0.000046	0.00053
	CNS	SF-295	>0.01	0.00024	>0.01	>0.01
	Renal	A498	>0.01	0.0000086	0.0097	>0.01
	Lung-NSC	NCI-460	0.0014	>0.01	0.00011	0.001
	Colon	KM20L2	0.0038	0.0070	0.00052	0.0013
	Melanoma	SK-MEL-3	>0.01	>0.01	>0.01	>0.01
Human cancer cells LC-50 ($\mu\text{g/ml}$)	Ovarian	OVCAR-3	>0.01	0.000088	>0.01	>0.01
	CNS	SF-295	>0.01	>0.01	>0.01	>0.01
	Renal	A498	>0.01	0.00029	>0.01	>0.01
	Lung-NSC	NCI-460	>0.01	>0.01	>0.01	>0.01
	Colon	KM20L2	>0.01	>0.01	>0.01	>0.01
	Melanoma	SK-MEL-3	>0.01	>0.01	>0.01	>0.01

From the foregoing, it is readily apparent that a useful embodiment of the present invention has been herein described and illustrated which fulfills all of the aforesaid objectives in a remarkably unexpected fashion.

Claims

1. A compound having the following structural formula




wherein R¹ is selected from the group consisting of OCH₃, NO₂, F, Cl, Br, and H; R² is selected from the group consisting of OCH₃, H and Cl; and R³ is selected from the group consisting of H and Cl, provided that if R¹ is NO₂, Cl,

F, or Br, $R^2=R^3=H$; that if $R^2=Cl$ then $R^1=R^3=H$; that if $R^3=Cl$ then $R^1=R^2=H$ and that if $R^1=OCH_3$, then $R^2=R^1$ and $R^3=H$.

2. A compound according to Claim 1 wherein $R^1=H$ or Cl , $R^2=H$ or Cl and $R^3=Cl$ or H .


3. A compound having the following structural formula



wherein R^4 is selected from the group consisting of H and CH_3 , R^5 is selected from the group consisting of H and CH_3 , R^6 is selected from the group consisting of CH_3 and H , R^7 is selected from the group consisting of H and OH , and R^8 is selected from the group consisting of H and OH ; provided that either R^7 or $R^8=OH$, that at least one of R^4 , R^5 and $R^6=CH_3$ and that at least two of R^4 , R^5 , R^6 , R^7 and $R^8=H$.

4. A compound according to Claim 3 wherein $R^4=H$, $R^5=CH_3$, $R^6=H$, $R^7=OH$ or H , $R^8=OH$ or H and $R^7 \neq R^8$.


5. A compound having the formula



ne.


for use in medicine.

6. A compound having the formula



15
for use in medicine.


7. The use of a compound having the following structural formula:



35
wherein R^1 is selected from the group consisting of OCH_3 , NO_2 , F, Cl, Br, and H; R^2 is selected from the group consisting of OCH_3 , H, and Cl, and R^3 is selected from the group consisting of H and Cl, provided that if R^1 is NO_2 , Cl, F, or Br, $R^2=R^3=H$; that if $R^2=Cl$ then $R^1=R^3=H$; that if $R^3=Cl$, then $R^1=R^2=H$ and that if $R^1=OCH_3$, then $R^2=R^1$ and $R^3=H$ in the manufacture of a medicament for inhibiting the growth of cancer cells selected from the group of cell lines consisting of P388, OVCAR-3, SF295, A498, NCI-460, KM20L2 and SK-MEL-3.

8. The use according to Claim 7 wherein $R^1=H$ or Cl, $R^2=H$ or Cl, and $R^3=Cl$ or H.

9. The use of a compound having the following structural formula:



55
wherein R^4 is selected from the group consisting of H and CH_3 , R^5 is selected from the group consisting of H and CH_3 , R^6 is selected from the group consisting of CH_3 and H, R^7 is selected from the group consisting of H and OH, and R^8 is selected from the group consisting of H and OH; provided that either R^7 or $R^8=OH$, that at least one of R^4 , R^5 and $R^6=CH_3$ and that at least two of R^4 , R^5 , R^6 , R^7 and $R^8=H$ in the manufacture of a medicament for inhibiting the growth of cancer cells selected from the group of cell lines consisting of P388, OVCAR-3, SF295, A498,

NCI-460, KM20L2 and SK-MEL-3.

10. The use according to Claim 9 wherein $R^4=H$, $R^5=CH_3$, $R^6=H$, $R^7=OH$ or H , $R^8=OH$ or H , and $R^7 \neq R^8$.


5 Patentansprüche

1. Verbindung der folgenden Strukturformel:

10

15

20



worin bedeuten:

25

R^1 OCH_3 , NO_2 , F , Cl , Br oder H ;
 R^2 OCH_3 , H oder Cl , und
 R^3 H oder Cl , wobei gilt, daß im Falle, daß R^1 für NO_2 , Cl , F oder Br steht, $R^2=R^3=H$; daß $R^2=Cl$, $R^1=R^3=H$;
daß $R^3=Cl$, $R^1=R^2=H$ und daß $R^1=OCH_3$, $R^2=R^1$ und $R^3=H$.


30

2. Verbindung nach Anspruch 1, wobei $R^1=H$ oder Cl , $R^2=H$ oder Cl und $R^3=Cl$ oder H .

3. Verbindung der folgenden Strukturformel

35

40



worin bedeuten:

45


R^4 H oder CH_3 , R^5 H oder CH_3 , R^6 CH_3 oder H ; R^7 H oder OH und
 R^8 H oder OH , wobei gilt, daß im Falle, daß einer der Reste R^7 oder R^8 für OH steht, mindestens einer der
Reste R^4 , R^5 und R^6 CH_3 darstellt und daß mindestens zwei der Reste R^4 , R^5 , R^6 , R^7 und R^8 H bedeuten.

50

4. Verbindung nach Anspruch 3, wobei $R^4=H$, $R^5=CH_3$, $R^6=H$, $R^7=OH$ oder H , $R^8=OH$ oder H und $R^7 \neq R^8$.


5. Verbindung der Formel

55




15 zur Verwendung in der Medizin.

6. Verbindung der Formel



30 zur Verwendung in der Medizin.

7. Verwendung einer Verbindung der folgenden Strukturformel




worin bedeuten:

50 R^1 OCH_3 , NO_2 , F, Cl, Br oder H;
 R^2 OCH_3 , H oder Cl, und
 R^3 H oder Cl, wobei gilt, daß im Falle, daß R^1 für NO_2 , Cl, F oder Br steht, $R^2=R^3=H$; daß $R^2=Cl$, $R^1=R^3=H$;
daß $R^3=Cl$, $R^1=R^2=H$ und daß $R^1=OCH_3$, $R^2=R^3$ und $R^3=H$, bei der Herstellung eines Medikaments zur Hem-
mung des Wachstums von Krebszellen, ausgewählt aus der Gruppe von aus P388, OVCAR-3, SF295, A498,
55 NCI-460, KM20L2 und SK-MEL-3 bestehenden Zelllinien.

8. Verwendung nach Anspruch 7, wobei $R^1=H$ oder Cl, $R^2=H$ oder Cl und $R^3=Cl$ oder H.

9. Verwendung einer Verbindung der folgenden Strukturformel




worin bedeuten:

- 15 R^4 H oder CH_3 , R^5 H oder CH_3 , R^6 CH_3 oder H; R^7 H oder OH und R^8 H oder OH, wobei gilt, daß im Falle, daß einer der Reste R^7 oder R^8 für OH steht, mindestens einer der Reste R^4 , R^5 und R^6 CH_3 darstellt und daß mindestens zwei der Reste R^4 , R^5 , R^6 , R^7 und R^8 H bedeuten, bei der Herstellung eines Medikaments zur Hemmung des Wachstums von Krebszellen, ausgewählt aus der Gruppe von aus P388, OVCAR-3, SF295, A498, NCI-460, KM20L2 und SK-MEL-3 bestehenden Zelllinien.

- 20 10. Verwendung nach Anspruch 9, wobei $R^4=\text{H}$, $R^5=\text{CH}_3$, $R^6=\text{H}$, $R^7=\text{OH}$ oder H, $R^8=\text{OH}$ oder H und $R^7 \neq R^8$.

Revendications


- 25 1. Composé ayant la formule structurelle suivante



- 40 dans laquelle R^1 est choisi dans le groupe composé de OCH_3 , NO_2 , F, Cl, Br, et H; R^2 est choisi dans le groupe composé de OCH_3 , H et Cl; et R^3 est choisi dans le groupe composé de H et Cl, à condition que si R^1 est NO_2 , Cl, F ou Br, $R^2=R^3=\text{H}$; que si $R^2=\text{Cl}$, alors $R^1=R^3=\text{H}$; que si $R^3=\text{Cl}$, alors $R^1=R^2=\text{H}$ et que si $R^1=\text{OCH}_3$, alors $R^2=R^1$ et $R^3=\text{H}$.

- 45 2. Composé selon la revendication 1, dans lequel $R^1=\text{H}$ ou Cl, $R^2=\text{H}$ ou Cl et $R^3=\text{Cl}$ ou H.

3. Composé ayant la formule structurelle suivante



- dans laquelle R^4 est choisi dans le groupe composé de H et CH_3 , R^5 est choisi dans le groupe composé de H et

CH₃, R⁶ est choisi dans le groupe composé de CH₃ et H, R⁷ est choisi dans le groupe composé de H et OH, et R⁸ est choisi dans le groupe composé de H et OH ; à condition que soit R⁷, soit R⁸=OH, qu'au moins un des R⁴, R⁵ et R⁶=CH₃, et qu'au moins deux des R⁴, R⁵, R⁶, R⁷ et R⁸=H.

4. Composé selon la revendication 3, dans lequel R⁴=H, R⁵=CH₃, R⁶=H, R⁷=OH ou H, R⁸=OH ou H et R⁷≠R⁸.
5. Composé de formule

10

15

20

utilisable en médecine.

25

6. Composé de formule

30

35

utilisable en médecine.

7. Utilisation d'un composé ayant la formule structurelle suivante :

40

45

50

55


dans laquelle R¹ est choisi dans le groupe composé de OCH₃, NO₂, F, Cl, Br, et H ; R² est choisi dans le groupe composé de OCH₃, H et Cl ; et R³ est choisi dans le groupe composé de H et Cl, à condition que si R¹ est NO₂, Cl, F ou Br, R²=R³=H ; que si R²=Cl, alors R¹=R³=H ; que si R³=Cl, alors R¹=R²=H et que si R¹=OCH₃, alors R²=R¹ et R³=H, dans la fabrication d'un médicament destiné à inhiber la croissance de cellules cancéreuses choisies dans le groupe des lignées cellulaires composé de P388, OVCAR-3, SF295, A498, NCI-460, KM20L2 et SK-MEL-3.

8. Utilisation selon la revendication 7, dans laquelle $R^1=H$ ou Cl, $R^2=H$ ou Cl, et $R^3=Cl$ ou H.

9. Utilisation d'un composé ayant la formule structurelle suivante :

5

10



15

dans laquelle R⁴ est choisi dans le groupe composé de H et CH₃, R⁵ est choisi dans le groupe composé de H et CH₃, R⁶ est choisi dans le groupe composé de CH₃ et H, R⁷ est choisi dans le groupe composé de H et OH, et R⁸ est choisi dans le groupe composé de H et OH ; à condition que soit R⁷, soit R⁸=OH, qu'au moins un des R⁴, R⁵ et R⁶=CH₃, et qu'au moins deux des R⁴, R⁵, R⁶, R⁷ et R⁸=H, dans la fabrication d'un médicament destiné à inhiber la croissance de cellules cancéreuses choisies dans le groupe des lignées cellulaires composé de P388, OVCAR-3, SF295, A498, NCI-460, KM20L2 et SK-MEL-3.

20

10. Utilisation selon la revendication 9, dans laquelle R⁴=H, R⁵=CH₃, R⁶=H, R⁷=OH ou H, R⁸=OH ou H et R⁷≠R⁸.

25

30

35

40

45

50

55